The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 18, 2024

Filed:

Nov. 07, 2017
Applicant:

Genovie Ab, Södertälje, SE;

Inventors:

Reagan Micheal Jarvis, Stockholm, SE;

Ryan Edward Hill, Stockholm, SE;

Luke Benjamin Pase, Stockholm, SE;

Assignee:

Genovie AB, Södertälje, SE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/071 (2010.01); A61K 35/15 (2015.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0602 (2013.01); A61K 35/15 (2013.01); C07K 14/7051 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5156 (2013.01); C12N 2310/153 (2013.01); C12N 2310/18 (2013.01); C12N 2810/10 (2013.01);
Abstract

The present invention relates to A multicomponent system wherein a first component is an engineered antigen-presenting cell (eAPC) designated component A and a second component is a genetic donor vector, designated component C, for delivery of one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and/or an analyte antigenic molecule (aAM), wherein component A a. Lacks endogenous surface expression of at least one family of aAPX and/or aAM and b. Contains at least two genomic receiver GO sites, designated component B and component D, each for integration of at least one ORF encoding at least one aAPX and/or aAM, and component C is matched to a component B, and wherein component C is designed to deliver c. A single ORF encoding at least one aAPX and/or aAM or d. Two or more ORF encoding at least one aAPX and/or aAM, wherein the genomic receiver sites B and D are synthetic constructs designed for re-combinase mediated exchange (RMCE).


Find Patent Forward Citations

Loading…